Swedish Orphan Biovitrum

220,4 SEK -0,81 %

1 investor følger denne virksomhed

www.sobi.com/en/investors

Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.

Omsætning

18,79 mia.

EBIT %

20,29 %

P/E

24,71

Udbytteafkast, %

Kursmål

Anbefaling

Opdateret

NASDAQ Stockholm

SOBI

Daglig lav / høj pris

220 / 222,2 SEK

Markedsværdi

68,28 mia. SEK

Aktieomsætning

32,2 mio. SEK

Volumen

146 t

Finanskalender

Delårsrapport

18.07.2023

Delårsrapport

26.10.2023

Årsrapport

08.02.2024

Viser Alle indholdstyper

Swedish Orphan Biovitrum AB: Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

Selskabsmeddelelse25.05.2023

Swedish Orphan Biovitrum

Finanskalender

Swedish Orphan Biovitrum AB: Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

Swedish Orphan Biovitrum AB: EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

Swedish Orphan Biovitrum AB: Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

Swedish Orphan Biovitrum AB: Bulletin from Swedish Orphan Biovitrum (Sobi)'s Annual General Meeting (AGM)

Swedish Orphan Biovitrum AB: Sobi publishes Q1 2023 report: Continued solid progress

Swedish Orphan Biovitrum AB: Sobi to streamline nirsevimab contractual arrangements

Swedish Orphan Biovitrum AB: Sobi® publishes Annual and sustainability report for 2022

Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB: Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint

Swedish Orphan Biovitrum AB: Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A

Swedish Orphan Biovitrum AB: FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A

Swedish Orphan Biovitrum AB: Sobi publishes Q4 and FY 2022 report: a good year and a solid future

Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB (publ) ahead of the Annual General Meeting in 2023

Swedish Orphan Biovitrum AB (publ)'s Chairman of the Board Håkan Björklund will not be available for re-election at the Annual General Meeting 2023

Swedish Orphan Biovitrum AB: Sobi publishes Q3 2022 report

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB: FDA grants priority review to efanesoctocog alfa for people with haemophilia A

Swedish Orphan Biovitrum AB: Sobi publishes Q2 2022 report

Swedish Orphan Biovitrum AB: Sobi to license loncastuximab tesirine from ADC Therapeutics

Swedish Orphan Biovitrum AB: FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A